Experts weigh newer ROS1 inhibitors like taletrectinib, highlighting long responses, fewer CNS/GI side effects, and trial challenges in rare NSCLC.
Edgardo Santos Castillero, MD, FACP, FASCO
Advertisement
Edgardo S. Santos Castillero, MD, FACP, FASCO, is physician lead at The Oncology Institute, Lung Cancer Center of Excellence; clinical associate professor, Charles E. Schmidt College of Medicine, Florida Atlantic University; and president, Florida Society of Clinical Oncology.
Articles by Edgardo Santos Castillero, MD, FACP, FASCO
Edgardo Santos, MD, discusses ROS1+ NSCLC treatment advances, taletrectinib data, toxicity profiles, and emerging therapies from recent Case-Based Roundtables.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Type C Meeting Supports Phase 3 Design for DLL3-Targeted ADC in ES-SCLC
2
FDA Approval Sought for Selinexor Plus Ruxolitinib in Myelofibrosis
3
Zanidatamab/Chemo Achieves OS Benefit in HER2+ Gastroesopheageal Cancer
4
Gynecologic Cancer Trends, Testing, and Treatment Advances Explained
5